[go: up one dir, main page]

AR027398A1 - Derivados de indol-3-ilo - Google Patents

Derivados de indol-3-ilo

Info

Publication number
AR027398A1
AR027398A1 ARP010100595A ARP010100595A AR027398A1 AR 027398 A1 AR027398 A1 AR 027398A1 AR P010100595 A ARP010100595 A AR P010100595A AR P010100595 A ARP010100595 A AR P010100595A AR 027398 A1 AR027398 A1 AR 027398A1
Authority
AR
Argentina
Prior art keywords
derivatives
ilo
indol
enosis
nomm
Prior art date
Application number
ARP010100595A
Other languages
English (en)
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR027398A1 publication Critical patent/AR027398A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Derivados de indol-3-ilo de la formula general (1), donde A, B, X, R1, R2, R3, R4, R5, n o m m tienen el significado indicado en la reivindicacion 1 asícomo sus sales y solvatos fisiologicamente inofensivos son inhibidores de la integrina y se pueden aplicar para el tratamiento de trombosis, infarto delmiocardio, enfermedades cardíacas coronarias, arterioesclerosis, inflamaciones, tumores, osteoporosis, artritis reumática, enfermedad degenerativa macular,retinopatía diabética, infecciones y rest enosis después de angioplastía o en procesos patologicos que se originan o propagan debido a una angiogénesis.
ARP010100595A 2000-02-11 2001-02-09 Derivados de indol-3-ilo AR027398A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10006139A DE10006139A1 (de) 2000-02-11 2000-02-11 Indol-3-yl-Derivate

Publications (1)

Publication Number Publication Date
AR027398A1 true AR027398A1 (es) 2003-03-26

Family

ID=7630611

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010100595A AR027398A1 (es) 2000-02-11 2001-02-09 Derivados de indol-3-ilo

Country Status (27)

Country Link
US (1) US6743810B2 (es)
EP (1) EP1254133B9 (es)
JP (1) JP4938194B2 (es)
KR (1) KR20020073585A (es)
CN (1) CN1214026C (es)
AR (1) AR027398A1 (es)
AT (1) ATE293620T1 (es)
AU (2) AU2001231664C1 (es)
BR (1) BR0108154A (es)
CA (1) CA2399813C (es)
CO (1) CO5261548A1 (es)
CZ (1) CZ20022616A3 (es)
DE (2) DE10006139A1 (es)
EC (1) ECSP013923A (es)
ES (1) ES2240400T3 (es)
HU (1) HUP0302671A2 (es)
IL (1) IL151154A0 (es)
MX (1) MXPA02007732A (es)
NO (1) NO20023770D0 (es)
NZ (1) NZ521260A (es)
PE (1) PE20011125A1 (es)
PL (1) PL356427A1 (es)
PT (1) PT1254133E (es)
RU (1) RU2257380C2 (es)
SK (1) SK11152002A3 (es)
WO (1) WO2001058893A2 (es)
ZA (1) ZA200207273B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063790A1 (en) * 1996-05-31 2004-04-01 The Scripps Research Institute Methods for inhibition of angiogenesis
US20040138284A1 (en) * 2000-02-11 2004-07-15 Matthias Wiesner Indol-3-yl derivatives
US20040058915A1 (en) * 2000-08-29 2004-03-25 Khanna Ish Kumar Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists
SK5902003A3 (en) * 2000-11-01 2003-08-05 Merck Patent Gmbh Methods and compositions for the treatment of diseases of the eye
GB0028367D0 (en) * 2000-11-21 2001-01-03 Celltech Chiroscience Ltd Chemical compounds
WO2002060438A1 (en) * 2001-01-29 2002-08-08 3-Dimensional Pharmaceuticals, Inc. Substituted indoles and their use as integrin antagonists
US6872730B2 (en) 2001-04-27 2005-03-29 3-Dimensional Pharmaceuticals, Inc. Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
PT1411926E (pt) 2001-08-01 2005-10-31 Merck Patent Gmbh Inibidores de integrina para o tratamento de doencas oftalmicas
WO2003068253A1 (en) * 2002-02-14 2003-08-21 Merck Patent Gmbh Methods and compositions for the treatment of eye diseases
CN100339376C (zh) * 2002-08-30 2007-09-26 卫材R&D管理有限公司 含氮芳环衍生物
CA2521135A1 (en) * 2003-04-07 2004-10-28 Kalypsys, Inc. N-containing heteroaromatic compounds as modulators of ppars and methods of treating metabolic disorders
WO2004098498A2 (en) * 2003-04-28 2004-11-18 Bayer Pharmaceuticals Corporation Indole acetic acid derivatives and their use as pharmaceutical agents
US7211588B2 (en) 2003-07-25 2007-05-01 Zentaris Gmbh N-substituted indolyl-3-glyoxylamides, their use as medicaments and process for their preparation
DE10337863A1 (de) 2003-08-18 2005-03-17 Merck Patent Gmbh Verwendung von Chromen-4-on-Derivaten
AU2004283413B2 (en) * 2003-10-01 2010-09-02 Merck Patent Gmbh Alfavbeta3 and alfavbeta6 integrin antagonists as antifibrotic agents
EP1758856A2 (en) * 2004-05-04 2007-03-07 Novo Nordisk A/S Indole derivatives for the treatment of obesity
US8003806B2 (en) * 2004-11-12 2011-08-23 OSI Pharmaceuticals, LLC Integrin antagonists useful as anticancer agents
EP1676834A1 (en) * 2004-12-30 2006-07-05 Sanofi-Aventis Deutschland GmbH Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation
WO2007024294A2 (en) * 2005-05-03 2007-03-01 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
CN102335168B (zh) * 2011-10-25 2014-04-02 合肥博太医药生物技术发展有限公司 吲哚-3-甲醇、二吲哚甲烷及其衍生物在制备治疗骨质疏松药物中的应用
AR094812A1 (es) * 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
KR102344105B1 (ko) 2014-08-18 2021-12-29 에자이 알앤드디 매니지먼트 가부시키가이샤 모노시클릭 피리딘 유도체의 염 및 이의 결정
JP6503450B2 (ja) 2015-03-25 2019-04-17 国立研究開発法人国立がん研究センター 胆管癌治療剤
SG10201913213WA (en) 2015-12-17 2020-03-30 Eisai R&D Man Co Ltd Therapeutic agent for breast cancer
CN111712245A (zh) 2018-03-28 2020-09-25 卫材R&D管理有限公司 用于肝细胞癌的治疗剂

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT290523B (de) * 1962-01-05 1971-06-11 Merck & Co Inc Verfahren zur Herstellung neuer α-(3-Indolyl)-carbonsäuren
GB1148908A (en) * 1965-04-19 1969-04-16 Sumitomo Chemical Co Indole derivatives and processes for making them
US4824850A (en) * 1982-05-18 1989-04-25 University Of Florida Brain-specific drug delivery
US4983615A (en) * 1989-06-28 1991-01-08 Hoechst-Roussel Pharmaceuticals Inc. Heteroarylamino- and heteroaryloxypyridinamine compounds which are useful in treating skin disorders
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
IT1244548B (it) * 1991-02-06 1994-07-15 Poli Ind Chimica Spa Derivati della 5-oxo-l-prolina e loro applicazioni farmaceutiche
GB9225141D0 (en) * 1992-12-01 1993-01-20 Smithkline Beecham Corp Chemical compounds
WO1997037655A1 (en) * 1996-04-10 1997-10-16 Merck & Co., Inc. αvβ3 ANTAGONISTS
AU4091697A (en) * 1996-08-27 1998-03-19 American Home Products Corporation 4-aminoethoxy indoles as dopamin d2 agonists and as 5ht1a ligands
AU1687699A (en) * 1997-12-25 1999-07-19 Yamanouchi Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivatives
DE69932414T2 (de) * 1998-02-23 2007-02-22 South Alabama Medical Science Foundation, Mobile Indol-3-propionsäure, salze und ester davon als arzneimittel #
CN1310706A (zh) * 1998-02-25 2001-08-29 遗传研究所有限公司 磷脂酶抑制剂
WO1999051575A1 (en) * 1998-04-08 1999-10-14 American Home Products Corporation N-aryloxyethyl-indoly-alkylamines for the treatment of depression (5-ht1a receptor active agents)
DK1068184T3 (da) * 1998-04-08 2002-12-30 Wyeth Corp N-aryloxyethylaminderivater til behandling af despression
JP4425699B2 (ja) * 2004-05-17 2010-03-03 川崎重工業株式会社 小型滑走艇

Also Published As

Publication number Publication date
CZ20022616A3 (cs) 2002-10-16
RU2002123332A (ru) 2004-01-10
US20030045728A1 (en) 2003-03-06
MXPA02007732A (es) 2002-10-11
EP1254133A2 (de) 2002-11-06
PE20011125A1 (es) 2001-11-07
PL356427A1 (en) 2004-06-28
CN1214026C (zh) 2005-08-10
DE50105955D1 (de) 2005-05-25
CA2399813A1 (en) 2001-08-16
US6743810B2 (en) 2004-06-01
AU2001231664C1 (en) 2006-10-05
JP4938194B2 (ja) 2012-05-23
ECSP013923A (es) 2002-09-27
AU2001231664B2 (en) 2006-02-23
RU2257380C2 (ru) 2005-07-27
NO20023770L (no) 2002-08-09
HUP0302671A2 (hu) 2003-12-29
EP1254133B1 (de) 2005-04-20
EP1254133B9 (de) 2005-09-07
DE10006139A1 (de) 2001-08-16
ZA200207273B (en) 2003-12-10
IL151154A0 (en) 2003-04-10
ES2240400T3 (es) 2005-10-16
NO20023770D0 (no) 2002-08-09
KR20020073585A (ko) 2002-09-27
AU3166401A (en) 2001-08-20
JP2003530319A (ja) 2003-10-14
WO2001058893A3 (de) 2002-04-18
HK1051863A1 (en) 2003-08-22
CN1398264A (zh) 2003-02-19
NZ521260A (en) 2004-02-27
BR0108154A (pt) 2003-01-21
ATE293620T1 (de) 2005-05-15
PT1254133E (pt) 2005-09-30
WO2001058893A2 (de) 2001-08-16
SK11152002A3 (sk) 2003-01-09
CA2399813C (en) 2010-03-09
CO5261548A1 (es) 2003-03-31

Similar Documents

Publication Publication Date Title
AR027398A1 (es) Derivados de indol-3-ilo
ES2183332T3 (es) Aminoacidos biciclicos aromaticos.
PA8518701A1 (es) Derivados de tiofeno utiles como agentes anticancerosos
DK1525177T3 (da) Substituerede 1,3-diphenylprop-2-en-1-on-derivater, fremstilling og anvendelse deraf
ES2180945T3 (es) Agentes antimicrobianos derivados de azolilpiperazinilfeniloxazolidona.
AR035320A1 (es) Compuestos activadores de hppardelta, composicion farmaceutica, su uso en la preparacion de medicamentos, metodo para el tratamiento de enfermedades mediadas por hppardelta
ATE225341T1 (de) In 6-position durch thio substituierte paclitaxele
UY26926A1 (es) Derivados de la quinolina y quinazolina
DK1115701T3 (da) Arylsulfonanilidurinstoffer
AR045016A1 (es) Derivados de 5-carbamimidoi-2-metilsulfaniltiofen-3-sulfonil como inhibidores conjugados de la cascada de complemento y su uso en el tratamiento de enfermedades.
DK0939627T3 (da) Pentaflourbenzensulfonamider og analoger
TR200200068T2 (tr) Nematisital triflüorobütenler
BR0008310A (pt) Derivados de alfa-alanina
PA8529501A1 (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa -7."
NO20010203L (no) Diacylhydrazinderivater som integrininhibitorer
BR0308195A (pt) Derivados de isoquinolina
BR0116202A (pt) Derivados de uréia e uretano como inibidores de integrinas
AR026267A1 (es) Agentes heterociclicos citotoxicos.
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
CA2348391A1 (en) Chromenone and chromanone derivatives as integrin inhibitors
BR0012391A (pt) Derivados de diacilidrazina
ATE248845T1 (de) Arylsulfonanilid-phosphate
BR0113373A (pt) Derivados bifenila e o uso dos mesmos como inibidores de integrina
ATE298328T1 (de) Taxan-derivate für die behandlung von krebs
ECSP982414A (es) Aminoacidos aromaticos biciclicos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal